Gerardo Hernandez net worth and biography

Gerardo Hernandez Biography and Net Worth

CFO of TransMedics Group

Mr. Hernandez is an accomplished finance leader with over 25 years of experience across the healthcare and consumer packaged goods (CPG) sectors. He most recently served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals, a biopharmaceutical company focused on RNAi therapeutics. In this role, Mr. Hernandez led a global team as the company scaled rapidly. Prior to his role at Alnylam, Mr. Hernandez spent nearly a decade at Shire, where he rose through the organization, eventually leading corporate FP&A. During his tenure, Shire was acquired by Takeda in a $62 billion transaction, after which he was instrumental in the integration effort. Mr. Hernandez began his career at Unilever where he held several finance roles of increasing responsibility before joining Shire in 2010. Mr. Hernandez holds a Bachelor of Science degree in Finance from the University of Wisconsin, La Crosse and an MBA in Strategy and Economics from Fundação Getulio Vargas, Sao Paulo, Brazil.

What is Gerardo Hernandez's net worth?: The estimated net worth of Gerardo Hernandez is at least $2.14 million as of December 4th, 2025. Hernandez owns 15,064 shares of TransMedics Group stock worth more than $2,138,485 as of January 14th. This net worth estimate does not reflect any other assets that Hernandez may own. Learn More about Gerardo Hernandez's net worth.
How do I contact Gerardo Hernandez?: The corporate mailing address for Hernandez and other TransMedics Group executives is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. TransMedics Group can also be reached via phone at (978) 552-0900 and via email at [email protected]. Learn More on Gerardo Hernandez's contact information.
Has Gerardo Hernandez been buying or selling shares of TransMedics Group?: Gerardo Hernandez has not been actively trading shares of TransMedics Group during the last ninety days. Most recently, Gerardo Hernandez sold 920 shares of the business's stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $139.62, for a transaction totalling $128,450.40. Following the completion of the sale, the chief financial officer now directly owns 15,064 shares of the company's stock, valued at $2,103,235.68. Learn More on Gerardo Hernandez's trading history.
Who are TransMedics Group's active insiders?: TransMedics Group's insider roster includes John Carey (VP), Nicholas Corcoran (Insider), Laura Damme (VP), Stephen Gordon (CFO), Waleed Hassanein (CEO), Gerardo Hernandez (CFO), Edwin Kania, Jr. (Director), Tamer Khayal (Insider), Miriam Provost (VP), Anil Ranganath (Insider), and David Weill (Director). Learn More on TransMedics Group's active insiders.
Are insiders buying or selling shares of TransMedics Group?: In the last year, insiders at the sold shares 8 times. They sold a total of 25,480 shares worth more than $3,310,247.26. The most recent insider tranaction occured on December, 4th when CFO Gerardo Hernandez sold 920 shares worth more than $128,450.40. Insiders at TransMedics Group own 7.0% of the company. Learn More about insider trades at TransMedics Group.
Information on this page was last updated on 12/4/2025.

Gerardo Hernandez Insider Trading History at TransMedics Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/4/2025	Sell	920	$139.62	$128,450.40	15,064

Gerardo Hernandez Buying and Selling Activity at TransMedics Group

TransMedics Group Company Overview

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Today's Range

Now: $141.96

$136.00

$142.95

50 Day Range

MA: $130.01

$113.40

$150.42

2 Week Range

Now: $141.96

$55.00

$156.00

Volume

921,512 shs

Average Volume

593,742 shs

Market Capitalization

$4.85 billion

P/E Ratio

57.47

Dividend Yield

N/A

Beta

2.03